Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on their proprietary ProCellEx®protein expression system.

Using ProCellEx, they are developing a proprietary pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins, based on thier plant cell-based expression technology, that primarily target large, established pharmaceutical markets and that rely in most cases upon known biological mechanisms of action.